NeuroOne Posts 38% Q4 Revenue Growth, Lands Record $4.5M Order
NMTC sits 29% above its 52-week low of $0.962.
Summary
NeuroOne reported preliminary Q4 FY2026 product revenue of $3.8 million, up 38.4% year-over-year from $2.7 million, and full-year revenue of $10.5 million, at the top of its guidance range of $9.2 million to $10.5 million. The company secured a record $4.5 million purchase order in September, with $1 million already shipped and the remaining $3.6 million expected to begin shipping during the first quarter of fiscal 2027 and into the second quarter, subject to manufacturing and delivery schedules. Open purchase orders reached $5.4 million as of September 30, 2026, for shipments through the first quarter of fiscal 2027, providing revenue visibility into next fiscal year. Product orders increased 24.2% in fiscal 2026 compared to fiscal 2025, while full-year product revenue increased 15.6% year-over-year. This follows a Q3 report that showed 16% revenue growth but cash of only $2.0 million and going concern doubt; the new order backlog may ease near-term liquidity concerns. Full audited results are expected in December 2026 with the 10-K filing.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — NeuroOne's remaining $3.6 million order is expected to ship in early fiscal 2027, subject to manufacturing and delivery schedules.
- Q4 Revenue — Q4 FY2026 product revenue was $3.8 million, up 38.4% from $2.7 million in Q4 FY2025.
- Full-Year Revenue — Full-year revenue was $10.5 million, at the top of guidance of $9.2 million to $10.5 million, up 15.6% year-over-year.
- Order Growth — Product orders increased 24.2% in fiscal 2026 compared to fiscal 2025.
- Open Orders — Open purchase orders were $5.4 million as of September 30, 2026, for shipments through the first quarter of fiscal 2027.
- Remaining Shipment — Shipments of the remaining $3.6 million are expected to begin in the first quarter of fiscal 2027 and into the second quarter, subject to manufacturing and delivery schedules.
All 6 details
- Shipments of remaining $3.6 million expected to begin during first quarter of fiscal 2027 and into second quarter of fiscal 2027, subject to manufacturing and delivery schedules.
- Q4 FY2026 product revenue of $3.8 million compared to $2.7 million in Q4 FY2025, representing year-over-year growth of 38.4%.
- Full-year revenue of $10.5 million was at the top of its guidance range of $9.2 million to $10.5 million.
- Product orders increased 24.2% in fiscal 2026 compared to fiscal 2025.
- Full-year product revenue for fiscal 2026 increased 15.6% year-over-year.
- Open purchase orders of $5.4 million as of September 30, 2026, are for shipments through the first quarter of fiscal 2027.
At the time of this announcement, NMTC was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.2M. The 52-week trading range was $0.96 to $6.96. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.